Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENTR-601-45 in Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping
NCT07038824Phase 2Recruiting
- Sponsor
- Entrada Therapeutics
- Start
- Aug 2025
- Primary completion
- Mar 2029
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 5
01
Overview
A Phase 2 trial of ENTR-601-45 in Duchenne muscular dystrophy (DMD), sponsored by Entrada Therapeutics. Started Aug 2025; status: recruiting.
02
Drugs
ENTR-601-45
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT07038824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07038824.